was created by healthcare professionals, for healthcare professionals.

Welcome recognizes that today’s cardiac and vascular professionals are working in a field that is continually evolving in terms of diagnostic, interventional, therapeutic procedures and patient care. New products and technologies are introduced and adopted every day. As a result, there is a need for a site dedicated solely to the non-physician professional, which provides in-depth coverage on current topics. Our site is designed for cardiac and vascular nurses, technologists, educators, managers, and directors, sharing the latest product insights, news, and education on one website.


Researchers Discover How To Prevent Calcification of Heart Tissue

December 6, 2016
“Researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have discovered that calcification of heart muscle tissue is caused when a type of cell called cardiac fibroblasts go awry. The scientists also found that blocking a molecular pathway in cardiac fibroblasts prevents heart calcification in mice.”

Interventional Council Perspective on Coronary Angiography and PCI Prior to TAVR

December 5, 2016
“The management of coronary artery disease (CAD) patients undergoing transcatheter aortic valve replacement (TAVR) should be individualized based on the patient’s overall clinical condition and anatomy, according to a council perspective from ACC’s Interventional Section Leadership Council, published Dec. 5 in JACC: Cardiovascular Interventions.”

Safety and Efficacy of Peri-Procedural Heparin Plus Short Term Infusion of Tirofiban Versus Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention: Results From The Intermountain Heart Collaborative Study

November 11, 2016
“Conclusion: During PCI, when comparing the efficacy of S- tirofiban versus bivalirudin, no significant differences for 30 day TIMI major bleeding or 1 year death, MI or UTVR were identified. Although trends towards reductions in both TIMI major bleeding and death were observed with the use of S-tirofiban, due to the generally low incidence of any adverse events, no statistical significance was reached.”

CMS has higher penalties for readmissions than for deaths

October 26, 2016
“If the Centers for Medicare & Medicaid Services (CMS) weighted 30-day readmissions and mortality equally, financial penalties in 2014 for U.S. hospitals would have substantially changed, according to an analysis of publicly available hospital data.


The researchers mentioned that financial penalties for readmissions under CMS’s programs are 10 times greater than they are for mortality.”